Oramed
| Company type | Public |
|---|---|
| Nasdaq: ORMP Russell Microcap Index component TASE: ORMP | |
| Industry | Biotech |
| Founded | 2006 |
| Headquarters | |
Key people | Nadav Kidron (CEO) |
| Website | oramed |
Oramed Pharmaceuticals Inc. (Hebrew: אורמד), is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
History
Oramed Pharmaceuticals was founded in 2006 by Miriam Kidron, a scientist at the Hadassah University Hospital in Jerusalem, and her son Nadav Kidron.[1][2]
Product pipeline
Oramed considers its flagship product to be an oral insulin capsule developed to treat sufferers of type 2 diabetes. The Company is currently conducting Phase 3 trials, under the FDA, for oral insulin in Type 2 diabetes.
In addition to the oral insulin capsule, Oramed is developing an exenatide-based capsule designed to balance blood sugar levels and control appetite, and is conducting clinical trials for the treatment of NASH with oral insulin.[3][4][5]
In 2021, Oramed created a subsidiary, Oravax Medical, to bring an oral Covid-19 vaccine to market.[6][7]
In January 2023, a Phase 3 trial of Oramed's orally administered insulin for Type 2 diabetes patients failed, thus causing the share price to plunge.[8] The company has mentioned that the pill worked for a subset of the population and will pursue a Phase 3 trial for that subset. [4]
In May 2023, Ben Shapiro invested $4.7 million and was named to the board of directors.[9]
On May 15, 2023, it was reported that Oramed's insulin pill was approved in China and will work with a Chinese firm to apply for marketing authorizations.[4][10]
Subsidiaries
OraTech Pharmaceuticals is a joint venture formed by Oramed Pharmaceuticals and Hefei Tianhui Biotech, to commercialize its insulin capsule and is expected to list on the NASDAQ sometime in 2025.
See also
References
- ^ Weinreb, Gali (15 January 2013). "Insulin pill co Oramed jumps on Nasdaq listing plans". Globes. Retrieved 16 February 2013.
- ^ Blackburn, Nicky (24 June 2007). "Israeli patent moves closer to achieving oral insulin treatment". Israel21c. Retrieved 16 February 2013.
- ^ Leichman, Abigail Klein (12 February 2013). "Groundbreaking insulin pill nearing market". ISRAEL21c. Retrieved 8 May 2025.
- ^ a b c "Oramed to reinitiate pivotal type 2 diabetes trial after Phase III flop". clinicaltrialsarena.com. 21 February 2024. Retrieved 3 May 2025.
- ^ "Oramed Pharmaceuticals Inc.: An emerging player in the huge orally delivered therapeutics segment of the global diabetes care market; we initiate our coverage with a price target of NIS 53.2" (PDF). mayafiles.tase.co.il.
- ^ "Israel developing injectable and oral vaccines as COVID cases soar". MobiHealthNews. 17 August 2021. Retrieved 8 May 2025.
- ^ "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post | JPost.com. 22 July 2021. Retrieved 8 May 2025.
- ^ "Oramed plunges after reporting trial failure". Globes. Retrieved 4 May 2023.
- ^ "Conservative Pundit Ben Shapiro Invests $4.7 Million in Israeli Drug Company". Bloomberg. Retrieved 4 May 2023.
- ^ Pharmaceuticals, Oramed (13 December 2018). "Oral Insulin Moves Towards Becoming Reality in U.S., China". Global Trade Magazine. Retrieved 8 May 2025.